Default company panoramic image
Homepage banner image

Gamma Therapeutics, Inc.

GT is an early stage biotech start up developing medical devices for cardiovascular disease risk assessment, surgical therapy & hemorrhage control.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Portland, OR, USA
  • Currency USD
  • Founded December 2009
  • Employees 3
  • Incorporation Type C-corp
  • Website

Company Summary

GT is an early stage biotech start-up, with early revenue, developing medical devices for cardiovascular disease risk assessment, surgical therapy and emergency response trauma care. GT's technology platform is natural human clotting proteins. GT's flagship product in mfg. is the GammaCoeur CVD Risk ELISA --a more sensitive, predictive CVD test to guide physicians in developing preventive care programs for cardiac at-risk patients.


  • Default avatar
    David Frederick Eastman, MS
    Chief Executive Officer

    35-year experienced Life Science industry executive developing & launching products & start-up ventures in medical devices, systems, & software; formerly interim CEO, Yecuris Corporation; prod mkt executive at Becton Dickinson, Cordis Dow Medical & Fresenius; OHSU Start Up Venture Advisory Group; BS in Mkt. & Comm, Univ. of No. Colorado; MS, Mkt., Bus, & Design, Univ. of OR., &; Exec. Medical Mkt. MBA Certificate, UCLA Anderson School of Mgmt..

  • Default avatar
    David Henry Farrell, PhD
    Founder & Chief Scientific Officer

    36-year researcher in thrombosis, hemostasis and coagulation research; Professor of Surgery, Department of Surgery, OHSU; Director, Health Sciences Entrepreneurship Certificate Program; Fellow of the American Heart Association; BS in Biochemistry, UCLA; PhD in Biological Sciences, Univ. of California, Irvine, Senior Fellow in Biochemistry, Univ. of Washington.


  • Default avatar
    Tonkon Torp
    Default avatar
    Candace Clement